Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly paclitaxel plus AMG 386 vs placebo in recurrent ovarian cancer
jRCT2080221277Phase 3
- Sponsor
- Takeda
- Start
- Oct 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Paclitaxel + AMG 386 with Paclitaxel + placebo (2 arms).
02
Drugs
trebananib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2080221277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221277.